- Home
- AVTX vs DOMH Comparison
AVTX vs DOMH Comparison
Compare AVTX & DOMH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | DOMH |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 69.2M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | AVTX | DOMH |
|---|---|---|
| Price | $18.99 | $4.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $32.29 | N/A |
| AVG Volume (30 Days) | ★ 341.4K | 311.8K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 14.52% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 9.19 |
| Revenue | $192,000.00 | ★ $99,588,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.50 |
| Revenue Growth | N/A | ★ 691.07 |
| 52 Week Low | $3.39 | $0.83 |
| 52 Week High | $20.72 | $13.58 |
Technical Indicators
Market Signals| Indicator | AVTX | DOMH |
|---|---|---|
| Relative Strength Index (RSI) | 53.63 | 49.59 |
| Support Level | $17.18 | $3.73 |
| Resistance Level | $20.20 | $4.68 |
| Average True Range (ATR) | 1.60 | 0.29 |
| MACD | -0.06 | 0.08 |
| Stochastic Oscillator | 59.35 | 60.89 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.